The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study
口服 Janus 激酶/脾酪氨酸激酶抑制剂 ASN002 显示出疗效，并能改善中重度特应性皮炎患者的相关全身炎症：一项随机双盲安慰剂对照研究的结果
期刊:British Journal of Dermatology
影响因子:9.6
doi:10.1111/bjd.17932
Bissonnette, R; Maari, C; Forman, S; Bhatia, N; Lee, M; Fowler, J; Tyring, S; Pariser, D; Sofen, H; Dhawan, S; Zook, M; Zammit, D J; Usansky, H; Denis, L; Rao, N; Song, T; Pavel, A B; Guttman-Yassky, E
